Merck beats estimates as Keytruda sales top $3 billion for first time

Merck & Co Inc blew past Wall Street expectations for third-quarter profit on Tuesday, as sales of its blockbuster immunotherapy Keytruda crossed the $3-billion mark for the first time in a quarter and beat lofty estimates.